Nestlé is set to acquire Aimmune in deal worth $2.6bn
Nestlé has announced plans to acquire allergy specialist Aimmune Therapeutics in a deal worth $2.6bn, six months after the biopharmaceutical company’s Palforzia became the first peanut allergy drug to be cleared for use in the US.
Currently, Nestlé has a 25% equity ownership stake in Aimmune, but is set to acquire the outstanding shares in an all-cash offer made through its health division, Nestlé Health Science. The deal is subject to customary closing conditions, although Nestlé expects the transaction to close in the fourth quarter of 2020.
"This transaction brings together Nestlé's nutritional science leadership with one of the most innovative companies in food allergy treatment," said Greg Behar, chief executive officer of Nestlé Health Science.
"Together we will be able to offer a wide range of solutions that can transform the lives of people suffering from food allergies around the world,” he added.
Read more: http://www.pmlive.com/pharma_news/nestle_is_set_to_acquire_aimmune_in_deal_worth_$2.6bn_1347578
Currently, Nestlé has a 25% equity ownership stake in Aimmune, but is set to acquire the outstanding shares in an all-cash offer made through its health division, Nestlé Health Science. The deal is subject to customary closing conditions, although Nestlé expects the transaction to close in the fourth quarter of 2020.
"This transaction brings together Nestlé's nutritional science leadership with one of the most innovative companies in food allergy treatment," said Greg Behar, chief executive officer of Nestlé Health Science.
"Together we will be able to offer a wide range of solutions that can transform the lives of people suffering from food allergies around the world,” he added.
Read more: http://www.pmlive.com/pharma_news/nestle_is_set_to_acquire_aimmune_in_deal_worth_$2.6bn_1347578
